icon-folder.gif   Conference Reports for NATAP  
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
Adherence with Telaprevir bid versus Every 8 Hour Dosing in Treatment-naïve HCV-infected Patients: Results from the Phase III OPTIMIZE Study
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
William Sievert,1 Maria Buti,2 Kosh Agarwal,3 Yves Horsmans,4 Stefan Zeuzem,5 Ewa Janczewska,6 Lisa Nyberg,7 Robert S Brown Jr,8 Christophe Hezode,9 Mario Rizzetto,10 Raymundo Parana,11 Sandra De Meyer,12 Ralph De Masi,13 Donghan Luo,13 James Witek13 1Monash Medical Centre and Monash University, Melbourne, Australia; 2Hospital Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain; 3Kings College Hospital, London, UK; 4Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; 5Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 6Outpatients Clinic for Hepatology, Myslowice, Poland; 7Kaiser Permanente, San Diego, CA, USA; 8Columbia University College of Physicians and Surgeons, New York, NY, USA; 9Hopital Henri Mondor, Créteil, France; 10University of Torino, Torino, Italy; 11Medical School, Federal University of Bahia, Bahia, Brazil; 12Janssen Infectious Diseases BVBA, Beerse, Belgium; 13Janssen Research & Development LLC, Titusville, NJ, USA